Press Releases

 
Press Releases
  Date Title View
Jun 24, 2004
BERKELEY, Calif., Jun 24, 2004 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today reported the successf...
Jun 22, 2004
BERKELEY, Calif., June 22 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today announced that a Phase II/III cli...
Jun 7, 2004
BERKELEY, Calif., June 7 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, will hold its annual shareholders meetin...
May 20, 2004
BERKELEY, Calif., May 20 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today announced that William J. Dawson, ...
May 19, 2004
BERKELEY, Calif., May 19 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today announced that its Phase II/III cl...
May 4, 2004
BERKELEY, Calif., May 4 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today reported financial results for the ...
Mar 29, 2004
BERKELEY, Calif., March 29 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today reported financial results for t...
Mar 29, 2004
In the news release, Dynavax Reports 2003 Fourth Quarter and Full Year Results, issued earlier today by Dynavax Technologies Corporation (Nasdaq: DVAX) over PR Newswire, the "Additional paid-in capital" line in the "Condensed Consolidated Balance Sheets" financial table should read "12,762" rather than "2,762," as incorrectly transmitted...
Mar 25, 2004
BERKELEY, Calif., March 25 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, will hold an earnings conference call ...
Mar 8, 2004
BERKELEY, Calif., March 8 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that Denise M. Gilbert, Ph.D., has joined its Board of Directors. Dr. Gilbert will also serve as chair of the Board's Audit Committee. With Dr. Gilbert's addition, Dynavax's Board of Directors increased to seven members....
FirstPrevious
...
41
NextLast
= add release to Briefcase